Related Experiment Videos
Cardioprotection: emerging pharmacotherapy
R J Gumina1, A Jahangir, G J Gross
1Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, Minnesota 55905, USA.
Insights
Acute coronary occlusion is a leading cause of death. Novel cardioprotective therapies aim to limit cardiomyocyte death from ischemia/reperfusion injury, improving survival in acute coronary syndromes.
Area of Science:
- Cardiovascular Medicine
- Cellular Biology
- Pharmacology
Background:
- Acute coronary occlusion is a leading global cause of mortality.
- Reperfusion therapy improves survival in acute coronary syndromes but has time limitations for myocardial salvage.
- Cardiomyocyte susceptibility to ischemia/reperfusion injury is a key factor limiting patient survival.
Purpose of the Study:
- To review the fundamental mechanisms of ischemia/reperfusion injury.
- To examine novel cardioprotective mechanisms for limiting or delaying myocyte death.
- To discuss clinical evidence for myocardial protective therapies in acute coronary syndromes.
Main Methods:
- Review of recent scientific literature on ischemia/reperfusion injury.
- Analysis of emerging therapeutic strategies targeting cardiomyocyte protection.
- Evaluation of clinical trial data for cardioprotective agents.
Main Results:
- Significant progress in understanding ischemia/reperfusion injury mechanisms.
- Development of novel therapeutic candidates aimed at reducing myocyte death.
- Identification of key targets for cardioprotection.
Conclusions:
- Cardiomyocyte protection is crucial for improving outcomes in acute coronary syndromes.
- Emerging therapies hold promise for enhancing myocardial salvage beyond current reperfusion strategies.
- Further clinical investigation is warranted for novel cardioprotective agents.
Abstract:
By the year 2020, it is predicted that acute coronary occlusion will be the major cause of death in the world. Recent advances in reperfusion therapy have substantially improved survival of patients with acute coronary syndromes. While early reperfusion reduces mortality, a time limitation exists with regard to myocardial salvage. In fact, the major limiting factor in further improving survival of patients with myocardial ischaemia is the susceptibility of the cardiomyocyte to ischaemic insult and lethal cell injury. Over the last decade substantial progress has been made in our understanding of the fundamental mechanisms of ischaemia/reperfusion injury. From this work novel means which limit or delay myocyte death have emerged and are currently under development as therapeutic candidates for the management of acute coronary syndromes. This report examines cardioprotective mechanisms and reviews clinical evidence for myocardial protective therapies.